Trials / Available

AvailableNCT03778424

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Status: Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Eisai Inc. · Industry
Sex: All
Age: 4 Years
Healthy volunteers: —

Summary

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Conditions

Lennox Gastaut Syndrome

Interventions

Type	Name	Description
DRUG	Rufinamide	Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).

Timeline

First posted: 2018-12-19
Last updated: 2025-07-17

Locations

2 sites across 1 country: Poland

Source: ClinicalTrials.gov record NCT03778424. Inclusion in this directory is not an endorsement.